ResearcherCanbas Co., Ltd. (Japan)Active in the last 2 years

Taichi Kawabe

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5113758183. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2024: 1 paper

Papers 1

A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreat… Last author DOI 10.1016/j.ejca.2024.113950 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Donald Richards · 1 shared paper, 2024 · strength 0.17
- Paper A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line trea… DOI 10.1016/j.ejca.2024.113950 ↗
Thomas Enzler · 1 shared paper, 2024 · strength 0.17
- Paper A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line trea… DOI 10.1016/j.ejca.2024.113950 ↗
Mark M. Zalupski · 1 shared paper, 2024 · strength 0.17
- Paper A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line trea… DOI 10.1016/j.ejca.2024.113950 ↗
Vaibhav Sahai · 1 shared paper, 2024 · strength 0.17
- Paper A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line trea… DOI 10.1016/j.ejca.2024.113950 ↗
Wells A. Messersmith · 1 shared paper, 2024 · strength 0.17
- Paper A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line trea… DOI 10.1016/j.ejca.2024.113950 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.